Industry
Biotechnology
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 10:35 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 6:14 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 9:26 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 9:24 pm
Portfolio Pulse from totan@benzinga.com
July 30, 2024 | 8:23 pm
Portfolio Pulse from Benzinga Newsdesk
June 06, 2024 | 11:50 pm
Portfolio Pulse from Benzinga Insights
June 06, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 1:53 pm
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
May 16, 2024 | 12:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.